Major insider transactions were disclosed on Wednesday, highlighting a mix of strategic purchases and mandatory sales across several U.S. listed companies.
Zentalis Pharmaceuticals Inc. (ZNTL) reported a director-level purchase of 4.34 million shares on August 14, 2026, at $3.50 per share for a total of $15.17 million. The Walters Group, a 10% owner and director entity, increased its beneficial ownership to 17.84 million shares. The stock has declined 11% over the past week but remains up 140% year-over-year.
Bakkt Inc. (BKKT) saw a director purchase 296,567 Class A shares on August 18, 2026, at a weighted-average price of $7.12, totaling $2.11 million. The transaction occurred as the stock traded near its 52-week low of $6.75, down 33% over the past six months.
Universal Safety Products Inc. recorded purchases by director Milton C. Ault III between August 17 and 19, 2026, totaling $201,392. The transactions included direct and indirect purchases at prices ranging from $3.83 to $5.87 per share.
Advanced Flower Capital Inc. (AFCG) reported a director purchase of 12,841 shares on August 19, 2026, at prices between $3.48 and $3.50 for a total of $44,686. The stock has gained 27% over the past week and 65% over six months.
Brilliant Earth Group Inc. (BRLT) disclosed CEO Beth Tamara Gerstein’s purchase of 10,000 Class A shares between August 18 and 19, 2026, for $12,532 at prices between $1.25 and $1.26 per share. The stock is near its 52-week low of $1.00 and has fallen 36% over the past year.
On the sell side, Astera Labs Inc. (ALAB) reported mandatory sales by President and CEO Sanjay Gajendra and CEO Jitendra Mohan on August 17, 2026, to cover tax obligations on vested restricted stock units. Each sold 86,180 shares at prices between $333.60 and $352.11, totaling approximately $30.8 million per executive. The stock currently trades at $289.80, up nearly 118% over six months.
Adaptive Biotechnologies Corp (ADPT) disclosed CEO Chad M. Robins sold approximately $14.88 million worth of shares between August 17 and 18, 2026, following stock option exercises. The sales occurred at prices between $24.48 and $25.57 per share, with the stock near its 52-week high of $26.16 after a 107% gain over the past year.
PACS Group Inc. (PACS) reported CEO Jason Hulse Murray sold 236,116 shares between August 17 and 19, 2026, under a prearranged trading plan adopted in May 2026. The sales totaled $10.44 million at prices between $43.34 and $44.85 per share.
